AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23672851 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber breakfast (360 kcals)
Number of subjects: 0
Study 23672851 — intervention group
Group type: COMPARATOR
Intervention: Skipping breakfast
Number of subjects: 0
Study 23672851 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal carbohydrate breakfast consumed ad libitum
Number of subjects: 0
Study 21378581 — intervention group
Group type: EXPERIMENTAL
Intervention: Castile soap solution
Number of subjects: 111
Study 21378581 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 111
Study 21378581 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure pulsatile lavage
Number of subjects: 111
Study 21378581 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure pulsatile lavage
Number of subjects: 111
Study 21378581 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcome scores (EuroQol-5 dimensions and short form-12)
Number of subjects: 111
Study 19766213 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 0
Study 19766213 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 0
Study 17927463 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (nurse-initiated call)
Number of subjects: 6106
Study 17927463 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 6106
Study 16107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4809
Study 16107485 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4809
Study 16107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (in patients with ACS)
Number of subjects: 4809
Study 16107485 — intervention group
Group type: COMPARATOR
Intervention: Abciximab (in patients with ACS)
Number of subjects: 4809
Study 16107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (in patients without ACS)
Number of subjects: 4809
Study 16107485 — intervention group
Group type: COMPARATOR
Intervention: Abciximab (in patients without ACS)
Number of subjects: 4809
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGFBP-3
Number of subjects: 51
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 51
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholinesterase
Number of subjects: 51
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prealbumin
Number of subjects: 51
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AST
Number of subjects: 51
Study 12511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ALT
Number of subjects: 51
Study 9430592 — intervention group
Group type: EXPERIMENTAL
Intervention: Light pulses presented to the popliteal region (behind the knee)
Number of subjects: 0
Study 9430592 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of body temperature and melatonin concentrations
Number of subjects: 0
Study 9430592 — intervention group
Group type: EXPERIMENTAL
Intervention: Implications for treatment development
Number of subjects: 0
Study 8132134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 100 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8
Study 8132134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 200 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8
Study 8132134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 500 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8
Study 8132134 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study 2818278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol therapy (twice daily)
Number of subjects: 62
Study 2818278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1205846 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different oil bath products at increased concentrations
Number of subjects: 30
Study 1205846 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of oil bath products
Number of subjects: 30
Study 1205846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath water temperature increased from 32 degrees to 38 degrees C
Number of subjects: 30
Study 27780887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise music intervention
Number of subjects: 50
Study 27780887 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (writing down 'if … then …' sentences)
Number of subjects: 50
Study 27780887 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study 27780887 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 50
Study 27812689 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel (ACT)
Number of subjects: 1251
Study 27812689 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab (ACTH)
Number of subjects: 1251
Study 27812689 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in patients with FCGR3A-158V/V or FCGR3A-158V/F genotypes
Number of subjects: 1251
Study 25467566 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS‐2 mechanical chest compression
Number of subjects: 4471
Study 25467566 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR (control)
Number of subjects: 4471
Study 23222289 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg, 2 capsules)
Number of subjects: 200
Study 23222289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 200
Study 21631929 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg tablet once daily; Day 2-18) and concomitant formoterol (24 μg twice daily; Day 12-18)
Number of subjects: 27
Study 21631929 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 μg twice daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18)
Number of subjects: 27
Study 21631929 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast and formoterol administered concomitantly
Number of subjects: 27
Study 21631929 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast and formoterol administered individually
Number of subjects: 27
Study 19459520 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (Telmisartan 80 mg/day)
Number of subjects: 80
Study 19459520 — intervention group
Group type: COMPARATOR
Intervention: Control (ACE inhibitors only, Enalapril 40 mg/day)
Number of subjects: 80
Study 16776692 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 61
Study 16776692 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic noxious conditioning stimulation (HNCS)
Number of subjects: 61
Study 15110063 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Steps (HS)
Number of subjects: 439
Study 15110063 — intervention group
Group type: EXPERIMENTAL
Intervention: PrePare (PP) + Healthy Steps (HS)
Number of subjects: 439
Study 15110063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (HS or PP+HS)
Number of subjects: 439
Study 15110063 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal intervention (PP)
Number of subjects: 439
Study 15110063 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 439
Study 11251427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (Fastrach)
Number of subjects: 0
Study 11251427 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 0
Study 9934807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg per day
Number of subjects: 37
Study 9934807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8038358 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg t.d.s. plus tetracycline 500 mg q.d.s. for 14 days (OMP/TCN)
Number of subjects: 44
Study 8038358 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg in the morning plus tetracycline 500 mg q.d.s. along with bismuth subsalicylate tablets 2 q.d.s. for 14 days (OMP/TCN/BSS)
Number of subjects: 44
Study 3055941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-buffered aspirin
Number of subjects: 0
Study 3055941 — intervention group
Group type: COMPARATOR
Intervention: Plain aspirin
Number of subjects: 0
Study 3055941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31134713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory training
Number of subjects: 95
Study 31134713 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Cogmed and metacognitive strategy training
Number of subjects: 95
Study 31134713 — intervention group
Group type: COMPARATOR
Intervention: Adaptive visual search training (control group)
Number of subjects: 95
Study 29400697 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 96
Study 29400697 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 96
Study 28061873 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg enterally administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Number of subjects: 850
Study 28061873 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Number of subjects: 850
Study 26488565 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 4577
Study 26488565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4577
Study 23159582 — intervention group
Group type: EXPERIMENTAL
Intervention: T pouch diversion after radical cystoprostatectomy
Number of subjects: 68
Study 23159582 — intervention group
Group type: COMPARATOR
Intervention: Studer pouch diversion after radical cystoprostatectomy
Number of subjects: 68
Study 21513602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-sitting exercise intervention
Number of subjects: 34
Study 21513602 — intervention group
Group type: COMPARATOR
Intervention: Control group (semirecumbent position)
Number of subjects: 34
Study 18381534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 6393
Study 17048435 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg DEC plus 400 mg ABZ
Number of subjects: 28
Study 17048435 — intervention group
Group type: COMPARATOR
Intervention: 300 mg DEC alone
Number of subjects: 28
Study 12663845 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant users (cocaine or amphetamines)
Number of subjects: 233
Study 12663845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol misusers only
Number of subjects: 233
Study 12663845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and cannabis users
Number of subjects: 233
Study 12663845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis users only
Number of subjects: 233
Study 12663845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 233
Study 10492061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (1000/400 mg) with artesunate (250 mg)
Number of subjects: 12
Study 10492061 — intervention group
Group type: COMPARATOR
Intervention: Atovaquone-proguanil (1000/400 mg) without artesunate
Number of subjects: 12
Study 8909421 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low-dose oral methotrexate
Number of subjects: 56
Study 8909421 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRIs
Number of subjects: 56
Study 2275513 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage oral contraceptives
Number of subjects: 280
Study 2275513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 453287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorotrianisene (Tace)
Number of subjects: 50
Study 453287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31486620 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB at L2
Number of subjects: 22
Study 31486620 — intervention group
Group type: COMPARATOR
Intervention: QLB at L4
Number of subjects: 22
Study 29160424 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic non-invasive ventilation (positive pressure 10 cm H2O, duration 1 hour, after 3 applications within the first 26 hours after extubation)
Number of subjects: 50
Study 29160424 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard physical therapy without non-invasive ventilation)
Number of subjects: 50
Study 26331110 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiron™ sirolimus‐eluting stent (SES)
Number of subjects: 57
Study 26331110 — intervention group
Group type: COMPARATOR
Intervention: Cronus™ bare metal stent (BMS)
Number of subjects: 57
Study 23898817 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural self-help (ICBT) combined with attention bias modification (ABM)
Number of subjects: 133
Study 23898817 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive-behavioural self-help (ICBT) combined with control training
Number of subjects: 133
Study 22316073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg for children ≥ 12 months, and 10 mg for those < 12 months) once daily for seven days
Number of subjects: 352
Study 22316073 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for seven days
Number of subjects: 352
Study 20204996 — intervention group
Group type: EXPERIMENTAL
Intervention: If-then implementation intention
Number of subjects: 557
Study 20204996 — intervention group
Group type: EXPERIMENTAL
Intervention: Global implementation intention
Number of subjects: 557
Study 20204996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 557
Study 17984834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Daclizumab (steroid-free)
Number of subjects: 70
Study 17984834 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + Corticosteroids
Number of subjects: 70
Study 17984834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (MMF) + Daclizumab (steroid-free)
Number of subjects: 70
Study 17984834 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + MMF + Corticosteroids
Number of subjects: 70
Study 17984834 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free protocol
Number of subjects: 70
Study 17984834 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid protocol
Number of subjects: 70
Study 16305899 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized cardiopulmonary bypass (MCPB)
Number of subjects: 30
Study 16305899 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 30
Study 12066265 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic bearings (345 hips)
Number of subjects: 514
Study 12066265 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome-on-polyethylene bearing (169 hips)
Number of subjects: 514
Study 10371880 — intervention group
Group type: EXPERIMENTAL
Intervention: NUPRO Gold active gel
Number of subjects: 60
Study 10371880 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel without the active agent
Number of subjects: 60
Study 7631676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation for 3 weeks
Number of subjects: 73
Study 7631676 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 73
Study 2449021 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 50
Study 2449021 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1.6 g daily
Number of subjects: 50
Study 30835574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal oral contraceptive use
Number of subjects: 16
Study 30835574 — intervention group
Group type: COMPARATOR
Intervention: No hormonal contraceptive use
Number of subjects: 16
Study 28874181 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and low glycemic index diet (1.3-1.4 g/kg/day)
Number of subjects: 120
Study 28874181 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (0.8-1.0 g/kg/day of protein)
Number of subjects: 120
Study 25914962 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 142
Study 25914962 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with interval debulking (NACT‐IDS)
Number of subjects: 142
Study 25914962 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimally debulked patients
Number of subjects: 142
Study 23340316 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 52
Study 23340316 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk β casein A2
Number of subjects: 52
Study 23340316 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk β casein A1
Number of subjects: 52
Study 23340316 — intervention group
Group type: COMPARATOR
Intervention: Washout epoch
Number of subjects: 52
Study 21170734 — intervention group
Group type: COMPARATOR
Intervention: 3,000 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Number of subjects: 0
Study 21170734 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Number of subjects: 0
Study 21170734 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Number of subjects: 0
Study 21170734 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 0
Study 19008771 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (given to 69% of children)
Number of subjects: 177
Study 19008771 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 174)
Number of subjects: 177
Study 19770794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (lower than therapeutically equivalent dose)
Number of subjects: 383
Study 19770794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 383
Study 19770794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (not prescribed a higher milligram dose)
Number of subjects: 383
Study 19770794 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (control group)
Number of subjects: 383
Study 16235158 — intervention group
Group type: EXPERIMENTAL
Intervention: InDuo
Number of subjects: 110
Study 11176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based directive
Number of subjects: 401
Study 11176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based directive
Number of subjects: 401
Study 11176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of directive with patient
Number of subjects: 401
Study 11176768 — intervention group
Group type: EXPERIMENTAL
Intervention: No discussion of directive with patient
Number of subjects: 401
Study 11176768 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no advance directive)
Number of subjects: 401
Study 11176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion interventions
Number of subjects: 401
Study 9671009 — intervention group
Group type: EXPERIMENTAL
Intervention: Local investigator interpretation of admission ECG
Number of subjects: 516
Study 8148290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 48
Study 8148290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 48
Study 8148290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with epinephrine
Number of subjects: 48
Study 8148290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine with epinephrine
Number of subjects: 48
Study 8148290 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (5 micrograms/mL)
Number of subjects: 48
Study 8148290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epinephrine)
Number of subjects: 48
Study 3061941 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 30
Study 3061941 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 30
Study 3061941 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 30
Study 3061941 — intervention group
Group type: EXPERIMENTAL
Intervention: methaqualone
Number of subjects: 30
Study 3061941 — intervention group
Group type: EXPERIMENTAL
Intervention: benzodiazepines
Number of subjects: 30
Study 3061941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 28993404 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPED intervention for secondary school PE teachers (workshops, online learning, implementation tasks, mentoring sessions)
Number of subjects: 1421
Study 28993404 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPED intervention for secondary school PE teachers
Number of subjects: 1421
Study 30020510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab with pertuzumab
Number of subjects: 370
Study 30020510 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus trastuzumab without pertuzumab
Number of subjects: 370
Study 26292796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing exercises
Number of subjects: 27
Study 26292796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vocal facilitating techniques)
Number of subjects: 27
Study 24151990 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative disconfirmation experience (worse than expected) in the high-risk estimate condition
Number of subjects: 0
Study 24151990 — intervention group
Group type: COMPARATOR
Intervention: Positive disconfirmation experience (better than expected) in the low-risk estimate condition
Number of subjects: 0
Study 22016458 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction
Number of subjects: 39
Study 22016458 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (immobilization and physiotherapy)
Number of subjects: 39
Study 19282417 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 44